Peptides for gut health and digestion
Your gut lining replaces itself every few days, and a lot can interfere — stress, medications, inflammation. This topic collects articles on how digestive tissue heals and where peptides for gut health fit into that research, especially BPC-157, which is based on a protective protein found in stomach juice.
Expect plain explanations of mechanisms and honest readings of the evidence, most of it preclinical. Anything offered through Promise is prescription-only: a licensed provider decides whether it's appropriate for you.
10 articles on this topic
-
KPV Peptide Benefits: What the Evidence Shows
KPV's strongest benefit signals are lower inflammatory activity in cultured cells and mouse colitis models. No human trial has established a KPV benefit, dose, or safety profile.
-
BPC-157 Benefits: What the Evidence Actually Shows
BPC-157 has been studied across connective tissue, gut, inflammatory, nerve, and vascular models. The catch is decisive: most findings come from animals or cells, not controlled human trials.
-
Semaglutide Sulfur Burps: Why They Happen
Sulfur-smelling burps are a real but poorly measured digestive complaint with semaglutide. Trials counted belching, not its smell, and the likely explanation combines slower digestion with hydrogen-sulfide gas.
-
BPC-157 for Inflammation: What the Evidence Shows
Rodent studies report smaller gut lesions, lower oxidative-stress measures and altered inflammatory signaling. No human trial has shown that BPC-157 lowers inflammation.
-
KLOW vs GLOW: What KPV Adds to the Blend
KLOW and GLOW share BPC-157, TB-500, and GHK-Cu; KLOW adds KPV, an inflammation-focused tripeptide backed by cell and mouse studies—not blend-level human trials.
-
Tirzepatide Constipation: How Long It Lasts
Tirzepatide constipation is common, especially in the first weeks and after dose increases. It often eases as treatment stabilizes, while severe or persistent symptoms need a clinician’s attention.
-
Semaglutide Constipation: What Helps
Semaglutide constipation is common during initiation and dose escalation. It usually eases, but it can last longer than other stomach side effects and deserves a clear plan with the prescriber.
-
Oral BPC-157: Do Capsules Work?
Oral activity has been reported in rat gut models, but capsules have not been tested in human trials and their absorption in people has not been measured. A capsule label cannot close that evidence gap.
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
KPV Peptide and the Gut Inflammation Evidence
KPV is the C-terminal tripeptide of alpha-MSH, and in mice whose MC1R does not function, every animal in the KPV-treated group survived DSS colitis — a result that points away from melanocortin receptors entirely.